Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, Piontkowsky D, Martin H, Haubrich R, McNicholl IR, Gallant J. Maggiolo F, et al. HIV Med. 2023 Jan;24(1):27-36. doi: 10.1111/hiv.13319. Epub 2022 May 8. HIV Med. 2023. PMID: 35527425 Free PMC article. Clinical Trial.
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Ferrazzi E, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Palù G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Suter F, Vella S, Lazzarin A; Italian HIV Guidelines Working Group. Antinori A, et al. New Microbiol. 2011 Apr;34(2):109-46. Epub 2011 Apr 30. New Microbiol. 2011. PMID: 21617825 Free article. No abstract available.
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL; Study 145 Team. Molina JM, et al. Lancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18. Lancet Infect Dis. 2012. PMID: 22015077 Clinical Trial.
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
d'Arminio Monforte A, Gianotti N, Cozzi-Lepri A, Pinnetti C, Andreoni M, di Perri G, Galli M, Poli A, Costantini A, Orofino G, Maggiolo F, Mazzarello G, Celesia BM, Luciani F, Lazzarin A, Sighinolfi L, Rizzardini G, Bonfanti P, Perno CF, Antinori A; ICONA Foundation Cohort. d'Arminio Monforte A, et al. Among authors: maggiolo f. Antivir Ther. 2014;19(3):319-24. doi: 10.3851/IMP2687. Epub 2013 Sep 13. Antivir Ther. 2014. PMID: 24036891
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM; VIKING-3 Study Group. Castagna A, et al. Among authors: maggiolo f. J Infect Dis. 2014 Aug 1;210(3):354-62. doi: 10.1093/infdis/jiu051. Epub 2014 Jan 19. J Infect Dis. 2014. PMID: 24446523 Free PMC article. Clinical Trial.
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Mocroft A, et al. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25826420 Free PMC article.
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Mocroft A, et al. Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17. Lancet HIV. 2016. PMID: 26762990 Clinical Trial.
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort.
d'Arminio Monforte A, Cozzi-Lepri A, Maggiolo F, Rizzardini G, Manconi PE, Gianotti N, Quirino T, Pinnetti C, Rusconi S, De Luca A, Antinori A; Icona Foundation Study cohort. d'Arminio Monforte A, et al. Among authors: maggiolo f. PLoS One. 2016 Jun 27;11(6):e0156360. doi: 10.1371/journal.pone.0156360. eCollection 2016. PLoS One. 2016. PMID: 27348592 Free PMC article.
337 results